Latest Biotech News

Bionova Scientific struck a manufacturing alliance with genetic delivery company Syenex to expand global access to plasmid DNA for viral and mRNA production; the partnership will make Bionova a...

Phanes Therapeutics reported positive Phase 2 results for spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, in combination with chemotherapy as first‑line treatment for...

Researchers at the University of Manchester reported an ATP‑free enzyme‑driven method for nucleotide triphosphate synthesis—an advance the authors argue could lower costs and environmental...

Johnson & Johnson announced a voluntary most‑favored‑nation (MFN) pricing agreement with the White House aimed at improving U.S. drug access, leaving AbbVie and Regeneron as the only major firms...

Aktis Oncology priced an upsized IPO that raised $318 million, selling shares at $18 apiece and opening trading with a sharp pop. The radiopharmaceutical developer’s debut signals renewed investor...

Multiple outlets reported that Merck is in discussions to acquire Revolution Medicines, with deal values reported in the $28–32 billion range. The talks, if they proceed, would provide Merck with...

Krystal Biotech disclosed early clinical data suggesting its mutation‑agnostic approach can deliver native CFTR protein to cystic fibrosis patients, and the company signaled plans to advance...

MIT spinout Boltz launched as a public benefit corporation with a $28 million seed round to commercialize high‑accuracy AI models for biomolecular structure prediction and therapeutic design....

Bionova Scientific and Syenex forged a plasmid DNA manufacturing alliance intended to expand global access to plasmids for lentiviral and mRNA production, combining Bionova’s IS‑free host platform...

Researchers reported novel imidazotetrazine derivatives that overcome temozolomide resistance in glioblastoma models, presenting a potential route to address a longstanding therapeutic gap in GBM....

Orca Bio secured $250 million to support the commercial launch of its allogeneic T‑cell therapy, a financing aimed at building manufacturing, commercialization and market access capabilities for...

Illumina named former NHGRI director Eric Green as chief medical officer, filling a long‑vacant role as the sequencing leader aims to accelerate clinical genomics adoption. In interviews, Green...

A wave of startups is positioning to exploit emerging FDA frameworks for bespoke, personalized gene‑editing therapies. One new CRISPR company is explicitly betting that regulators will ease...

The Biotechnology Innovation Organization launched the BIO Investment Council to improve capital formation for early‑stage biotech, pairing investors and emerging companies to tackle barriers to...

Aktis Oncology priced its IPO and raised $318 million, selling 17.65 million shares at $18 apiece. The Cambridge, Mass.-based radiopharmaceutical developer plans to use proceeds to advance its...

Eikon Therapeutics filed for a U.S. IPO, positioning the company as a potential bellwether for biotech public-market sentiment. The filing will be watched for demand signals around cutting-edge...

Krystal Biotech disclosed early clinical data indicating its gene therapy can deliver native protein to cystic fibrosis patients, and the company proposed advancing directly into a pivotal trial....

Phanes Therapeutics reported positive phase 2 results for spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, in combination with chemotherapy for first‑line treatment of...

Orca Bio closed $250 million in financing to support the commercial launch of its T‑cell therapy for complications after allogeneic stem cell transplants. The capital will underwrite manufacturing...

City of Hope and Cellares signed an agreement to evaluate Cellares’ automated Cell Shuttle manufacturing and Cell Q QC platform for City of Hope’s CAR T program targeting glioblastoma. The...